Alveolar soft part sarcoma: Prolonged response to immune checkpoint inhibitors
Ruetima Titapiwatanakun
Pediatric Hematology/Oncology, Department of Pediatrics, Cancer and Blood Disorders Center, Valley Children's Healthcare, Madera, California, USA
Search for more papers by this authorCrystal Farrell
Department of Radiology, Valley Children's Healthcare, Madera, California, USA
Search for more papers by this authorCorresponding Author
Karen S. Fernandez
Pediatric Hematology/Oncology, Department of Pediatrics, Cancer and Blood Disorders Center, Valley Children's Healthcare, Madera, California, USA
Pediatric Hematology/Oncology, Department of Pediatrics, Stanford University, Stanford, USA
Correspondence
Karen S. Fernández, Division of Pediatric Hematology/Oncology, Department of Pediatrics, Cancer and Blood Disorders Center, Valley Children's Hospital, 9300 Valley Children's Pl, Madera, CA 93736, USA.
Email: [email protected]
Search for more papers by this authorRuetima Titapiwatanakun
Pediatric Hematology/Oncology, Department of Pediatrics, Cancer and Blood Disorders Center, Valley Children's Healthcare, Madera, California, USA
Search for more papers by this authorCrystal Farrell
Department of Radiology, Valley Children's Healthcare, Madera, California, USA
Search for more papers by this authorCorresponding Author
Karen S. Fernandez
Pediatric Hematology/Oncology, Department of Pediatrics, Cancer and Blood Disorders Center, Valley Children's Healthcare, Madera, California, USA
Pediatric Hematology/Oncology, Department of Pediatrics, Stanford University, Stanford, USA
Correspondence
Karen S. Fernández, Division of Pediatric Hematology/Oncology, Department of Pediatrics, Cancer and Blood Disorders Center, Valley Children's Hospital, 9300 Valley Children's Pl, Madera, CA 93736, USA.
Email: [email protected]
Search for more papers by this author
REFERENCES
- 1Ladanyi M, Lui MY, Antonescu CR, et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene. 2001; 20(1): 48-57. doi:10.1038/sj.onc.1204074
- 2Zhang Y, Wang Y, Wang H, Wen C, Wu X. Alveolar soft part sarcoma in childhood and adolescence: report of three cases and review of literature. Front Pediatr. 2022; 10:937112. doi:10.3389/fped.2022.937112
- 3Stockwin LH, Vistica DT, Kenney S, et al. Gene expression profiling of alveolar soft-part sarcoma (ASPS). BMC Cancer. 2009; 9: 22. doi:10.1186/1471-2407-9-22
- 4Lieberman PH, Brennan MF, Kimmel M, Erlandson RA, Garin-Chesa P, Flehinger BY. Alveolar soft-part sarcoma. A clinico-pathologic study of half a century. Cancer. 1989; 63(1): 1-13. doi:10.1002/1097-0142(19890101)63:1<1::AID-CNCR2820630102>3.0.CO;2-E
10.1002/1097-0142(19890101)63:1<1::AID-CNCR2820630102>3.0.CO;2-E CAS PubMed Web of Science® Google Scholar
- 5Portera CA Jr, Ho V, Patel SR, et al. Alveolar soft part sarcoma. Cancer. 2001; 91(3): 585-591. doi:10.1002/1097-0142(20010201)91:3<585::AID-CNCR1038>3.0.CO;2-0
- 6Flores RJ, Harrison DJ, Federman NC, et al. Alveolar soft part sarcoma in children and young adults: a report of 69 cases. Pediatr Blood Cancer. 2018; 65(5):e26953. doi:10.1002/pbc.26953
- 7Reichardt P, Lindner T, Pink D, Thuss-Patience PC, Kretzschmar A, Dorken B. Chemotherapy in alveolar soft part sarcomas. What do we know? Eur J Cancer. 2003; 39(11): 1511-1516.
- 8Paoluzzi L, Maki RG. Diagnosis, prognosis, and treatment of alveolar soft-part sarcoma: a review. JAMA Oncol. 2018; 5(2): 254-260. doi:10.1001/jamaoncol.2018.4490
- 9Groisberg R, Roszik J, Conley AP, et al. Genomics, morphoproteomics, and treatment patterns of patients with alveolar soft part sarcoma and response to multiple experimental therapies. Mol Cancer Ther. 2020; 19(5): 1165-1172. doi:10.1158/1535-7163.MCT-19-0579
- 10Yang L, Wang C. Status and progress of drug therapy for alveolar soft tissue sarcoma. Chin J Cancer. 2019; 29: 746-752. doi:10.19401/j.cnki.1007-3639.2019.09.010
10.19401/j.cnki.1007?3639.2019.09.010 Google Scholar
